FDA Accepts Renewed Review of Troriluzole for Ataxia
The FDA accepted Biohaven’s resubmitted troriluzole application for spinocerebellar ataxia and set a first-quarter 2027 review goal. This procedural advance reopens a path to a decision, while the prior evidentiary objections remain the central…
